Skip to main content

Tm Bioscience Posts Higher Q3 Revenues, Net Loss

NEW YORK, Nov. 7 (GenomeWeb News) - Tm Bioscience reported today a doubling of its third-quarter revenues, despite a slight increase in its net loss, as research and development spending dropped about 43 percent.

 

For the third quarter, Tm's revenues jumped to $2.2 million from $1.1 million in the year-ago period.

 

The company's net loss for the quarter inched up to $3.1 million, or $.07 per share, from $3 million, or $.09 per share, a year earlier.

 

Tm's R&S costs in the third quarter dropped to $661,963 from about $1.2 million in the same quarter last year, although total expenses rose to roughly $4.5 million from about $4 million as the company added employees in the marketing and business development, finance and administration, technical support, and medical and regulatory areas.

 

As of Sept. 30, Tm had cash and cash equivalents totaling $537,768.  

 

The Scan

Possibly as Transmissible

Officials in the UK say the B.1.617.2 variant of SARS-CoV-2 may be as transmitted as easily as the B.1.1.7 variant that was identified in the UK, New Scientist reports.

Gene Therapy for SCID 'Encouraging'

The Associated Press reports that a gene therapy appears to be effective in treating severe combined immunodeficiency syndrome.

To Watch the Variants

Scientists told US lawmakers that SARS-CoV-2 variants need to be better monitored, the New York Times reports.

Nature Papers Present Nautilus Genome, Tool to Analyze Single-Cell Data, More

In Nature this week: nautilus genome gives peek into its evolution, computational tool to analyze single-cell ATAC-seq data, and more.